The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
n–3 Fatty Acids and Cardiovascular Outcomes in Patients with Dysglycemia
Open accessAbstract
BACKGROUND: The use of n-3 fatty acids may prevent cardiovascular events in patients with recent myocardial infarction or heart failure. Their effects in patients with (or at risk for) type 2 diabetes mellitus are unknown. METHODS: In this double-blind study with a 2-by-2 factorial design, we randomly assigned 12,536 patients who were at high risk for cardiovascular events and had impaired fasting glucose, impaired glucose tolerance, or diabetes to receive a 1-g capsule containing at least 900 mg (90% or more) of ethyl esters of n-3 fatty acids or placebo daily and to receive either insulin glargine or standard care. The primary outcome was death from cardiovascular causes. The results of the comparison between n-3 fatty acids and placebo are reported here. RESULTS: During a median follow up of 6.2 years, the incidence of the primary outcome was not significantly decreased among patients receiving n-3 fatty acids, as compared with those receiving placebo (574 patients [9.1%] vs. 581 patients [9.3%]; hazard ratio, 0.98; 95% confidence interval [CI], 0.87 to 1.10; P=0.72). The use of n-3 fatty acids also had no significant effect on the rates of major vascular events (1034 patients [16.5%] vs. 1017 patients [16.3%]; hazard ratio, 1.01; 95% CI, 0.93 to 1.10; P=0.81), death from any cause (951 [15.1%] vs. 964 [15.4%]; hazard ratio, 0.98; 95% CI, 0.89 to 1.07; P=0.63), or death from arrhythmia (288 [4.6%] vs. 259 [4.1%]; hazard ratio, 1.10; 95% CI, 0.93 to 1.30; P=0.26). Triglyceride levels were reduced by 14.5 mg per deciliter (0.16 mmol per liter) more among patients receiving n-3 fatty acids than among those receiving placebo (P<0.001), without a significant effect on other lipids. Adverse effects were similar in the two groups. CONCLUSIONS: Daily supplementation with 1 g of n-3 fatty acids did not reduce the rate of cardiovascular events in patients at high risk for cardiovascular events. (Funded by Sanofi; ORIGIN ClinicalTrials.gov number, NCT00069784.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Even among omega‐3 fatty acid studies, there are marked differences with respect to the relatively low doses of omega‐3 administered and the ratio of EPA to DHA.16, 17, 18, 19, 20, 21, 22, 23, 24”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the ORIGIN trial, which enrolled more than 12,000 patients with impaired fasting glucose and at high risk for cardiovascular events, the administration of 1 g/day of combined EPA + DHA (465 mg of EPA and 375 mg of DHA) had no impact on cardiovascular mortality [89].”
From Targeting triglycerides for cardiovascular risk reduction (2026) · cites this paper as [89]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“However, many previous 20 , 21 , 22 , 23 and recently completed clinical studies 24 , 25 showed that ω3 PUFA supplementation did not offer significant favorable impacts on cardiovascular events.”
From Association Between Omega-3 Fatty Acid Intake and Dyslipidemia: A Continuous Dose-Response Meta-Analysis of Randomized Controlled Trials (2023) · cites this paper as [20]
The cited source says what the claim attributes to it.
In the citing paper
“The STRENGTH, VITAL, ASCEND, ORIGIN, OMEGA, ALPHA-OMEGA, GISSI-HF and GISSI-P trials randomized patients to receive either a combination of EPA and DHA or placebo; yet only the GISSI trials noted a statistically significant effect on cardiovascular events and mortality [96–103].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [99]
The cited source says what the claim attributes to it.
In the citing paper
“but subsequent larger trials failed to replicate these findings. 8,9”
From Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk (2020) · cites this paper as [9]
The cited source says what the claim attributes to it.
In the citing paper
“Nevertheless, the dosage used in OMEMI was about twice that used in comparable earlier trials 5, 7, 23, 30 , although considerably lower than the dosage used in REDUCE-IT 14 , and also in the STRENGTH trial 36 .”
From Effects of n-3 Fatty Acid Supplements in Elderly Patients After Myocardial Infarction (2021) · cites this paper as [30]
The cited source says what the claim attributes to it.
In the citing paper
“A limitation to the study is the inclusion rate of 26 % of screened candidates, which is relatively low compared to other n-3 PUFA trials not targeting elderly patients 30-33 .”
From Effects of n-3 Fatty Acid Supplements in Elderly Patients After Myocardial Infarction (2021) · cites this paper as [30]
The cited source says what the claim attributes to it.
In the citing paper
“Other more recent omega‐3 therapy outcome studies conducted in the presence of statins have been less encouraging, but these studies were characterized by evaluating nonhypertriglyceridemic patient populations (eg, TG <200 mg/dL) and administering low doses of long‐chain omega‐3 fatty acids (eg, eicosapentaenoic acid [EPA] and/or docosoahexaenoic acid [DHA]).19, 20, 21, 22, 23, 24”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [21]
The cited source says what the claim attributes to it.
In the citing paper
“Our initial manuscript included Trials such as ORIGIN8, ASCEND9, Alpha Omega10, and JELIS5; among these trials, only one trial had IPE, and the rest of the trials had a combination of EPA and DHA, so our results were skewed as search strategy missed significant studies.”
From Cardiovascular outcomes and coronary artery disease prevention secondary to icosapent ethyl: a meta-analysis of randomized clinical trials (2024) · cites this paper as [8]
In the citing paper
“Data from studies on supplementation with n-3 fatty acids do not support recommending n-3 fatty acid supplements for secondary prevention of CVD in T2DM.86,87”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [86]
In the citing paper
“In the ORIGIN (Outcome Reduction With Initial Glargine Intervention) trial, 12 537 patients (mean age 63.5 years) at high CVD risk with impaired fasting glucose (IFG), impaired glucose tolerance (IGT), or T2DM were randomized to insulin glargine titrated to a fasting blood glucose level of ≤5.3 mmol/L (≤95 mg/dL) or standard care.86 After a median follow-up of 6.2 years, the incidence of CV”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [86]
In the citing paper
“The JELIS study692) conducted in Japan found that the addition of EPA to statins showed a significant preventive effect on major cardiovascular events compared to statin monotherapy.”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [692]
In the citing paper
“Evidence does not conclusively support recommending n-3 (eicosapentaenoic acid [EPA] and docosahexaenoic acid [DHA]) supplements for all people with diabetes for the prevention or treatment of cardiovascular events (70,209,210).”
From 5. Facilitating Positive Health Behaviors and Well-being to Improve Health Outcomes:Standards of Care in Diabetes—2023 (2023) · cites this paper as [210]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ESC/EAS Guidelines for the management of dyslipidaemias
Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549
Lichtenstein, A. H., Appel, L. J., Brands, M., Carnethon, M., Daniels, S., Franch, H. A., Franklin, B., Kris-Etherton, P., Harris, W. S., Howard, B., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.176158 · Cited by 2,705
(1999) · PubMed · Cited by 2,062
Basal insulin and cardiovascular and other outcomes in dysglycemia
The ORIGIN Trial Investigators (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203858 · Cited by 1,636
Self-citationGISSI-HF investigators (2008) · The Lancet · doi:10.1016/s0140-6736(08)61239-8 · Cited by 1,350
Fish and Omega-3 Fatty Acid Intake and Risk of Coronary Heart Disease in Women
Hu, F. B. (2002) · JAMA · doi:10.1001/jama.287.14.1815 · Cited by 1,018
n–3 Fatty Acids and Cardiovascular Events after Myocardial Infarction
Kromhout, D., Giltay, E. J., & Geleijnse, J. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003603 · Cited by 936
n–3 Fatty acids and cardiovascular disease: evidence explained and mechanisms explored
Calder, P. C. (2004) · Clinical Science · doi:10.1042/cs20040119 · Cited by 571
Cardiovascular effects of marine omega-3 fatty acids
Saravanan, P., Davidson, N. C., Schmidt, E. B., & Calder, P. C. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60445-x · Cited by 513
Flagged first, then by citations
Research works printed but not linked: 1
- Gerstein H, 2008, Am Heart J, 155, 26
Cited by
Sorted by citations
Items 301–400 of 933
Biomarkers of Fish Oil Omega‐3 Polyunsaturated Fatty Acids Intake in Humans
Silva, V., Barazzoni, R., & Singer, P. (2013) · Nutrition in Clinical Practice · doi:10.1177/0884533613516144 · Cited by 43
Effects of Omega-3 Fatty Acids on Major Adverse Cardiovascular Events
Sharma, G. V., Martin, S. S., & Blumenthal, R. S. (2020) · JAMA · doi:10.1001/jama.2020.22387 · Cited by 42
Omega-3 fatty acids for cardiovascular event lowering
Kaur, G., Mason, R. P., Steg, P. G., & Bhatt, D. L. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae003 · Cited by 41
Nishizaki, Y., Miyauchi, K., Iwata, H., Inoue, T., Hirayama, A., Kimura, K., Ozaki, Y., Murohara, T., Ueshima, K., Kuwabara, Y., et al. (2023) · American Heart Journal · doi:10.1016/j.ahj.2022.11.008 · Cited by 40
Bashir, B., Schofield, J., Downie, P., France, M., Ashcroft, D. M., Wright, A. K., Romeo, S., Gouni-Berthold, I., Maan, A., Durrington, P. N., et al. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1389106 · Cited by 40
Review of Cardiometabolic Effects of Prescription Omega-3 Fatty Acids
Burke, M. F., Burke, F. M., & Soffer, D. E. (2017) · Current Atherosclerosis Reports · doi:10.1007/s11883-017-0700-z · Cited by 40
Poole, C., Halcox, J., Jenkins‐Jones, S., Carr, E., Schifflers, M., Ray, K. K., & Currie, C. J. (2012) · Clinical Therapeutics · doi:10.1016/j.clinthera.2012.11.008 · Cited by 40
Ros, E., López‐Miranda, J., Picó, C., Rubio, M. Á., Babió, N., Sala‐Vila, A., Pérez‐Jiménez, F., Escrich, E., Bulló, M., Solanas, M., et al. (2015) · PubMed · doi:10.3305/nh.2015.32.2.9202 · Cited by 40
Omega-3 fatty acids and coronary heart disease. The final verdict?
Kromhout, D. (2012) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328359515f · Cited by 40
Omega-3 fatty acid and cardiovascular outcomes: insights from recent clinical trials
Jia, X., Kohli, P., & Virani, S. S. (2019) · Current Atherosclerosis Reports · doi:10.1007/s11883-019-0763-0 · Cited by 39
Scolaro, B., Kim, H. S. J., & de Castro, I. A. (2016) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2016.1235546 · Cited by 39
Morieri, M. L., Gao, H., Pigeyre, M., Shah, H., Sjaarda, J., Mendonça, C., Hastings, T., Buranasupkajorn, P., Motsinger‐Reif, A. A., Rotroff, D. M., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0709 · Cited by 39
Wang, Y., Fang, Y., Magliano, D. J., Charchar, F. J., Sobey, C. G., Drummond, G. R., & Golledge, J. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac124 · Cited by 39
Ooi, E. M. M., Barrett, P. H. R., & Watts, G. F. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.06.069 · Cited by 38
Turgeon, J., Dussault, S., Maingrette, F., Groleau, J., Haddad, P., Pérez, G., & Rivard, A. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.05.020 · Cited by 38
Halcox, J., & Misra, A. (2014) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2014.0049 · Cited by 38
Harris, W. S., Masson, S., Barlera, S., Milani, V., Pileggi, S., Franzosi, M. G., Marchioli, R., Tognoni, G., Tavazzi, L., & Latini, R. (2016) · Nutrition Research · doi:10.1016/j.nutres.2016.06.012 · Cited by 38
Blom, W. A. M., Koppenol, W. P., Hiemstra, H., Stojaković, T., Scharnagl, H., & Trautwein, E. A. (2018) · European Journal of Nutrition · doi:10.1007/s00394-018-1706-1 · Cited by 38
Sekikawa, A. M., Cui, C., Sugiyama, D., Fabio, A., Harris, W. S., & Zhang, X. (2019) · Nutrients · doi:10.3390/nu11112599 · Cited by 38
Itsiopoulos, C., Marx, W., Mayr, H. L., Tatucu-Babet, O. A., Dash, S. R., George, E. S., Trakman, G. L., Kelly, J. T., Thomas, C. J., & Brazionis, L. (2018) · Journal of Nutrition & Intermediary Metabolism · doi:10.1016/j.jnim.2018.02.002 · Cited by 37
Li, J., Dou, K., Zhou, Z., Zhao, D. H., Ye, P., Zhao, J., & Guo, L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1069992 · Cited by 37
Chen, L., Zhang, Q., Meng, Y., Zhao, T., Mu, C., Fu, C., Deng, C., Feng, J., Du, S., Liu, W., et al. (2023) · EMBO Reports · doi:10.15252/embr.202254731 · Cited by 37
Apolipoprotein C-III and cardiovascular diseases: when genetics meet molecular pathologies
Dib, I., Khalil, A., Chouaib, R., El-Makhour, Y., & Noureddine, H. (2021) · Molecular Biology Reports · doi:10.1007/s11033-020-06071-5 · Cited by 37
Omega-3 polyunsaturated fatty acids in the treatment of atherogenic dyslipidemia
Pirillo, A., & Catapano, A. L. (2013) · Atherosclerosis Supplements · doi:10.1016/s1567-5688(13)70004-7 · Cited by 37
Choi, G. Y., & Calder, P. C. (2024) · Frontiers in Nutrition · doi:10.3389/fnut.2024.1423228 · Cited by 36
Patterson, A. C., Metherel, A. H., Hanning, R. M., & Stark, K. D. (2013) · British Journal Of Nutrition · doi:10.1017/s0007114513002225 · Cited by 36
N-3 Fatty Acids for Prevention of Cardiovascular Disease
Khawaja, O. A., Gaziano, J. M., & Djoussé, L. (2014) · Current Atherosclerosis Reports · doi:10.1007/s11883-014-0450-0 · Cited by 36
Dai, W., Long, J., Cheng, Y., Chen, Y., & Zhao, S. (2018) · Scientific Reports · doi:10.1038/s41598-018-25835-5 · Cited by 36
Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia
Aseem Basha, M. (2019) · Journal of the Practice of Cardiovascular Sciences · doi:10.4103/jpcs.jpcs_16_19 · Cited by 36
Feingold, K. R., & Grünfeld, C. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-13177-6_14 · Cited by 35
Thambiah, S. C., & Lai, L. C. (2021) · Practical Laboratory Medicine · doi:10.1016/j.plabm.2021.e00248 · Cited by 35
Yessoufou, A., Nekoua, M. P., Gbankoto, A., Mashalla, Y., & Moutairou, K. A. (2015) · Journal of Diabetes Research · doi:10.1155/2015/731434 · Cited by 35
Current evidence and future perspectives on n−3 PUFAs
Pelliccia, F., Marazzi, G., Greco, C., Franzoni, F., Speziale, G., & Gaudio, C. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.06.044 · Cited by 35
History and future of omega-3 fatty acids in cardiovascular disease
Sperling, L. S., & Nelson, J. R. (2016) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1120190 · Cited by 34
Desnoyers, M., Kim, G., & Rousseau, G. (2018) · Marine Drugs · doi:10.3390/md16070234 · Cited by 34
Miao, Z., Schultzberg, M., Wang, X., & Zhao, Y. (2021) · Clinical Nutrition · doi:10.1016/j.clnu.2020.12.037 · Cited by 34
Metkus, T., Timpone, J., Leaf, D., Goetz, M. B., Harris, W., & Brown, T. (2013) · HIV Medicine · doi:10.1111/hiv.12046 · Cited by 34
Lucchesi, D., Russo, R., Gabriele, M., Longo, V. G., Prato, S. D., Penno, G., & Pucci, L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109298 · Cited by 34
Nutrient reference values for bioactives: new approaches needed? A conference report
Biesalski, H. K., Erdman, J. W., Hathcock, J. N., Ellwood, K. C., Beatty, S., Johnson, E. J., Marchioli, R., Lauritzen, L., Rice, H. B., Shao, A. E., et al. (2013) · European Journal of Nutrition · doi:10.1007/s00394-013-0503-0 · Cited by 34
Lombardi, M., Chiabrando, J. G., Vescovo, G. M., Bressi, E., Del Buono, M. G., Carbone, S., Koenig, R. A., Van Tassell, B. W., Abbate, A., Biondi-Zoccai, G., et al. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00865-5 · Cited by 33
Progress in the care of common inherited atherogenic disorders of apolipoprotein B metabolism
Ellis, K. L., Hooper, A. J., Burnett, J. R., & Watts, G. F. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.69 · Cited by 33
Congenital Lipodystrophies and Dyslipidemias
Prieur, X., May, C. L., Magré, J., & Cariou, B. (2014) · Current Atherosclerosis Reports · doi:10.1007/s11883-014-0437-x · Cited by 33
Chien, K., Lin, H., Hsu, H., Chen, P., Su, T., Chen, M.-F., & Lee, Y. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.06.015 · Cited by 33
Ambrosy, A. P., Yang, J., Sung, S. H., Allen, A. R., Fitzpatrick, J. K., Rana, J. S., Wagner, J., Philip, S., Abrahamson, D., Granowitz, C., et al. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.020377 · Cited by 32
Classes of Lipid Mediators and Their Effects on Vascular Inflammation in Atherosclerosis
Lubrano, V., Ndreu, R., & Balzan, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021637 · Cited by 33
Stauffer, M. E., Weisenfluh, L., & Morrison, A. (2013) · Vascular Health and Risk Management · doi:10.2147/vhrm.s52713 · Cited by 32
Reiner, M. F., Stivala, S., Limacher, A., Bonetti, N. R., Méan, M., Egloff, M., Rodondi, N., Aujesky, D., von Schacky, C., Lüscher, T. F., et al. (2017) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13553 · Cited by 32
Cardiovascular effects of omega-3 fatty acids: Hope or hype?
Jo, S., Han, S. H., Kim, S., Eckel, R. H., & Koh, K. K. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.02.014 · Cited by 32
Barbarawi, M., Lakshman, H. G., Barbarawi, O., Al‐Abdouh, A., kasasbeh, M. A., Djoussé, L., & Manson, J. E. (2021) · Contemporary Clinical Trials · doi:10.1016/j.cct.2021.106458 · Cited by 32
Emerging agents for the treatment and prevention of stroke: progress in clinical trials
Safouris, A., Magoufis, G., & Tsivgoulis, G. K. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1985463 · Cited by 32
Blood HER2 and Uromodulin as Causal Mediators of CKD
Sjaarda, J., Gerstein, H. C., Yusuf, S., Treleaven, D. J., Walsh, M. W., Mann, J. F. E., Hess, S., & Paré, G. (2018) · Journal of the American Society of Nephrology · doi:10.1681/asn.2017070812 · Cited by 32
Omega-3 Fatty Acids: A Growing Ocean of Choices
Fares, H., Lavie, C. J., DiNicolantonio, J. J., O’Keefe, J. H., & Milani, R. V. (2014) · Current Atherosclerosis Reports · doi:10.1007/s11883-013-0389-6 · Cited by 31
Does Supplementation with Omega-3 PUFAs Add to the Prevention of Cardiovascular Disease?
Rizos, E. C., & Elisaf, M. (2017) · Current Cardiology Reports · doi:10.1007/s11886-017-0856-8 · Cited by 31
Omega‐3 fatty acids for the prevention of atherosclerotic cardiovascular disease
Barry, A. R., & Dixon, D. L. (2021) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2615 · Cited by 31
Drug Therapy of Dyslipidemia in the Elderly
Yandrapalli, S., Gupta, S., Andries, G., Cooper, H. A., & Aronow, W. S. (2019) · Drugs & Aging · doi:10.1007/s40266-018-00632-x · Cited by 31
Lipid management for cardiovascular risk reduction in type 1 diabetes
Tell, S., Nadeau, K. J., & Eckel, R. H. (2020) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000551 · Cited by 30
Wong, A. T. Y., Chan, D. C., Barrett, P. H. R., Adams, L. A., & Watts, G. F. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-4037 · Cited by 30
Omega-3 PUFAs slow organ aging through promoting energy metabolism
Xiong, Y., Li, X., Liu, J., Luo, P., Zhang, H., Zhou, H., Ling, X., Zhang, M., Ye, L., Chen, Q., et al. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107384 · Cited by 30
Diet and Nutrition in Peripheral Artery Disease: A Systematic Review
Wan, D., Li, V., Banfield, L. E., Azab, S. M., de Souza, R. J., & Anand, S. S. (2022) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2022.01.021 · Cited by 30
Papademetriou, V., Nylén, E., Doumas, M. N., Probstfield, J., Mann, J. F. E., Gilbert, R. E., & Gerstein, H. C. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2017.05.047 · Cited by 30
Omega-3 Polyunsaturated Fatty Acids and Stroke Burden
Ueno, Y., Miyamoto, N., Yamashiro, K., Tanaka, R., & Hattori, N. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225549 · Cited by 30
Takkunen, M. J., de Mello, V. D., Schwab, U., Kuusisto, J., Vaittinen, M., Ågren, J. J., Laakso, M., Pihlajamäki, J., & Uusitupa, M. I. J. (2015) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201500594 · Cited by 29
Omega-3 polyunsaturated fatty acid supplementation in the prevention of cardiovascular disease
Walz, C. P., Barry, A. R., & Koshman, S. L. (2016) · Canadian Pharmacists Journal / Revue des Pharmaciens du Canada · doi:10.1177/1715163516640812 · Cited by 29
Hypertriglyceridemia in Diabetes Mellitus: Implications for Pediatric Care
Hartz, J. C., de Ferranti, S. D., & Gidding, S. S. (2018) · Journal of the Endocrine Society · doi:10.1210/js.2018-00079 · Cited by 29
Omega-3 and cardiovascular prevention – Is this still a choice?
Ruscica, M., Sirtori, C. R., Carugo, S., Calder, P. C., & Corsini, A. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106342 · Cited by 29
The ORIGIN Trial Investigators (2013) · Diabetes Care · doi:10.2337/dc12-2238 · Cited by 29
Self-citationKimmig, L. M., & Karalis, D. G. (2013) · Lipid Insights · doi:10.4137/lpi.s10846 · Cited by 29
Fatty Acids and Other Risk Factors for Sudden Cardiac Death in Patients Starting Hemodialysis
Friedman, A. N., Yu, Z., Denski, C., Tamez, H. E., Wenger, J., Thadhani, R., Li, Y., & Watkins, B. A. (2013) · American Journal of Nephrology · doi:10.1159/000351764 · Cited by 29
Complications of Diabetes Mellitus
Brownlee, M., Aiello, L. P., Cooper, M. E., Vinik, A. I., Plutzky, J., & Boulton, A. J. M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-29738-7.00033-2 · Cited by 29
Modulation of miRNA expression in aged rat hippocampus by buttermilk and krill oil
Crespo, M. C., Tomé‐Carneiro, J., Gómez‐Coronado, D., Burgos‐Ramos, E., García-Serrano, A. M., Martín‐Hernández, R., Baliyan, S., Fontecha, J., Venero, C., Dávalos, A., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-22148-5 · Cited by 29
Seth, J., Sharma, S., Leong, C. J., & Rabkin, S. W. (2024) · Antioxidants · doi:10.3390/antiox13080955 · Cited by 28
Predictive power of cell‐to‐cell variability
Li, B., & You, L. (2013) · Quantitative Biology · doi:10.1007/s40484-013-0013-3 · Cited by 28
The Role of Omega-3 Polyunsaturated Fatty Acids Supplementation in Childhood: A Review
Ciccone, M. M., Scicchitano, P., Gesualdo, M., Zito, A., Carbonara, S., Ricci, G., Cortese, F., & Giordano, P. (2013) · Recent Advances in Cardiovascular Drug Discovery (Formerly Recent Patents on Cardiovascular Drug Discovery) · doi:10.2174/1574890111308010006 · Cited by 28
Polyunsaturated Fatty Acids and Atherosclerosis: Insights from Pre‐Clinical Studies
Ramji, D. P. (2018) · European Journal of Lipid Science and Technology · doi:10.1002/ejlt.201800029 · Cited by 28
Controversies in omega-3 efficacy and novel concepts for application
Radcliffe, J., Thomas, J., Bramley, A. L., Kouris‐Blazos, A., Radford, B. E., Scholey, A. B., Pipingas, A., Thomas, C., & Itsiopoulos, C. (2016) · Journal of Nutrition & Intermediary Metabolism · doi:10.1016/j.jnim.2016.05.002 · Cited by 27
Sobrino, A., Walker, M. E., Colas, R. A., & Dalli, J. (2020) · PLoS ONE · doi:10.1371/journal.pone.0242543 · Cited by 27
Extrinsic and intrinsic modulators of inflammation-resolution signaling in heart failure
Rao, A., Gupta, A., Kain, V., & Halade, G. V. (2023) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00276.2023 · Cited by 27
Sanders, T. A. B. (2014) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.113.071555 · Cited by 27
Dietary management of dyslipidaemias. Is there any evidence for cardiovascular benefit?
Anagnostis, P. G., Paschou, S. Α., Goulis, D. G., Athyros, V. G., & Karagiannis, A. I. (2017) · Maturitas · doi:10.1016/j.maturitas.2017.11.011 · Cited by 27
Sekikawa, A. M., Mahajan, H., Kadowaki, S., Hisamatsu, T., Miyagawa, N., Fujiyoshi, A., Kadota, A., Maegawa, H., Murata, K., Miura, K., et al. (2018) · European Journal of Clinical Nutrition · doi:10.1038/s41430-018-0242-7 · Cited by 27
Zelniker, T. A., Morrow, D. A., Scirica, B. M., Furtado, J. D., Guo, J., Mozaffarian, D., Sabatine, M. S., & O’Donoghue, M. L. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.017401 · Cited by 26
Diabetic Cardiac Autonomic Neuropathy
Serhiyenko, V. A., & Serhiyenko, A. A. (2023) · Springer eBooks · doi:10.1007/978-3-031-25519-9_57 · Cited by 26
Current Treatment of Dyslipidemia: Evolving Roles of Non-Statin and Newer Drugs
KONES, R. J., & Rumana, U. (2015) · Drugs · doi:10.1007/s40265-015-0429-3 · Cited by 26
Yuan, T., Si, S., Li, Y., Li, W., Chen, X., Liu, C., Li, J., Wang, B., Hou, L., Liu, Y., et al. (2020) · Nutrition Journal · doi:10.1186/s12937-020-00582-4 · Cited by 26
Sanz, J., Moreno, P., & Fuster, V. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.06.045 · Cited by 27
Strand, E., Pedersen, E. R., Svingen, G. F. T., Schartum-Hansen, H., Rebnord, E. W., Bjørndal, B., Seifert, R., Bohov, P., Meyer, K., Hiltunen, J. K., et al. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-216 · Cited by 26
Behavioral Interventions for Antipsychotic Induced Appetite Changes
Werneke, U., Taylor, D. M., & Sanders, T. A. B. (2013) · Current Psychiatry Reports · doi:10.1007/s11920-012-0347-y · Cited by 26
Macchia, A., Romero, M., D'Ettorre, A., Tognoni, G., & Mariani, J. A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062772 · Cited by 26
Krantz, M. J., Havranek, E. P., Pereira, R. I., Beaty, B. L., Mehler, P. S., & Long, C. S. (2015) · Journal of Negative Results in BioMedicine · doi:10.1186/s12952-015-0040-x · Cited by 26
Dietary Intake of Omega-3 Fatty Acids From Fish and Risk of Diabetic Retinopathy
Chew, E. Y. (2017) · JAMA · doi:10.1001/jama.2017.1926 · Cited by 26
New evidence that omega-3 fatty acids have a role in primary prevention of coronary heart disease
Calder, P. C. (2017) · Journal of Public Health and Emergency · doi:10.21037/jphe.2017.03.03 · Cited by 26
Dyslipidemia Management in 2020: An Update on Diagnosis and Therapeutic Perspectives
Karantas, I. D., Okur, M. E., Okur, N. Ü., & Siafaka, P. I. (2020) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530320666200810144004 · Cited by 25
Miller, M. J., Tokgözoğlu, L. S., Parhofer, K. G., Handelsman, Y., Leiter, L. A., Landmesser, U., Brinton, E. A., & Catapano, A. L. (2022) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2022.2103541 · Cited by 25
Grant, J. K., Dangl, M. D., Ndumele, C. E., Michos, E. D., & Martin, S. S. (2023) · Journal of Lipid Research · doi:10.1016/j.jlr.2023.100493 · Cited by 25
Omega-3 fatty acids in primary and secondary prevention of cardiovascular diseases
Tutor, A. W., O’Keefe, E. L., Lavie, C. J., Elagizi, A., Milani, R. V., & O’Keefe, J. H. (2024) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2024.03.009 · Cited by 25
Wang, Y., Wu, G., Wang, Y., Rehman, A., Yu, L., Zhang, H., Jin, Q., Suleria, H. A. R., & Wang, X. (2024) · Food Chemistry · doi:10.1016/j.foodchem.2024.142498 · Cited by 25
Nutrition for the Prevention and Treatment of Chronic Kidney Disease in Diabetes
Whitham, D. (2014) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2014.07.222 · Cited by 25
Yamagata, K. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200403121952 · Cited by 25
Kim, K., Song, Y., Oh, T. J., Choi, S. H., & Jang, H. C. (2020) · Nutrients · doi:10.3390/nu12113365 · Cited by 25
Microbiota, a New Playground for the Omega-3 Polyunsaturated Fatty Acids in Cardiovascular Diseases
Rousseau, G. (2021) · Marine Drugs · doi:10.3390/md19020054 · Cited by 25
Metadata
- Authors
- The ORIGIN Trial Investigators
- Corresponding author
- The ORIGIN Trial Investigators
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-07-26
- Volume
- 367
- Issue
- 4
- Pages
- 309-318
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1560062315
- Semantic Scholar
- 00cc8344ced92b3c8921b97df8607e6b3032e111
- Cited by
- 929
- References
- 21
- Citations by year
- 2026: 19 · 2025: 23 · 2024: 41 · 2023: 53 · 2022: 51 · 2021: 57 · 2020: 76 · 2019: 60 · 2018: 72 · 2017: 56 · 2016: 90 · 2015: 79 · 2014: 90 · 2013: 122 · 2012: 38
- FWCI
- 97.82
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- Monash University Research Portal (Monash University) (publishedVersion, other-oa)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- HAL (submittedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- IRIS (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Topics
- Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Nutritional Studies and Diet
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- omega-3 fatty acids, cardiovascular outcomes, type 2 diabetes, dysglycemia, impaired fasting glucose, impaired glucose tolerance, insulin glargine, cardiovascular mortality, major vascular events, triglycerides, serum lipids, cardiac arrhythmias, cardiovascular risk reduction, dietary supplementation, omega-3 fatty acid ethyl esters
- MeSH terms
- Insulin Glargine, Aged, Cardiovascular Diseases, Cholesterol, Diabetes Mellitus, Type 2, Double-Blind Method, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Hypoglycemic Agents, Male, Middle Aged, Triglycerides, Fatty Acids, Omega-3, Incidence, Proportional Hazards Models, Treatment Failure, Glucose Intolerance, Insulin, Long-Acting, Intention to Treat Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
